| |
Presentation |
Webcast |
|
June 1, 2023
Investor call regarding license agreement in Japan
|
|
|
|
May 9, 2023
Business update with management team
|
|
|
|
April 20, 2023
Company presentation with CEO Jenny Sundqvist at Redeye Investor Forum Göteborg
|
|
|
|
March 28, 2023
Presentation with CEO Jenny Sundqvist and CDO Eva Arlander on the results of the PK study with cobitolimod
|
|
|
|
February 23, 2023
Interview with CEO Jenny Sundqvist regarding the year-end report for 2022
|
|
|
|
February 14, 2023
Presentation with CEO Jenny Sundqvist providing complementary information on the phase III program CONCLUDE with cobitolimod
|
|
|
|
February 13, 2023
Get to know interview with CEO Jenny Sundqvist
|
|
|
|
November 24, 2022
Redeye Life Science Day 2022 - In Focus Q&A
|
|
|
|
October 6, 2022
Presentation at Redeye Investor AW in Gothenburg
|
|
|
|
September 22, 2022
Deep dive presentation on the positive feedback from the Japanese regulatory authority (PMDA) on cobitolimod
|
|
|
|
June 9, 2022
Deep dive presentation on the commercialization strategy for cobitolimod
|
|
|
|
June 2, 2022
Redeye Growth Day 2022 In Focus Q&A
|
|
|
|
May 16, 2022
Q1 report interview with acting CEO Johan Giléus
|
|
|
|
March 31, 2022
Presentation at Redeye Investor Forum in Malmö
|
|
|
|
March 14, 2022
Capital Markets Day 2022
|
|
|
|
February 28, 2022
Deep dive into the mechanism of action of cobitolimod with CEO Peter Zerhouni and Senior Scientist Charlotte Admyre
|
|
|
|
February 25, 2022
Year-end report Interview with CEO Peter Zerhouni
|
|
|
|
January 27, 2022
CEO Peter Zerhouni and CMO Thomas Knittel make a deep dive into the design of the phase III study CONCLUDE
|
|
|
|
December 9, 2021
Presentation by CEO Peter Zerhouni at HC Andersen Capital's Virtual Growth Days Seminar
|
|
|
|
November 29, 2021
Interview with CEO Peter Zerhouni about the enrollment of the first patient in the phase III study CONCLUDE and the way forward
|
|
|
|
November 25, 2021
Presentation with CEO Peter Zerhouni at Erik Penser Banks Bolagsdag 2021
|
|
|
|
November 24, 2021
Presentation with CEO Peter Zerhouni and CMO Thomas Knittel on the highlights of the Q3 report and a deep dive into previous clinical studies with cobitolimod
|
|
|
|
November 11, 2021
Presentation at Redeye Life Science Day 2021
|
|
|
|
October 27, 2021
Company introduction at HC Andersen Capital's online event
|
|
|
|
October 7, 2021
Presentation at HC Andersen Capital Small & Mid cap seminar
|
|
|
|
September 2, 2021
Presentation at Pareto Securities’ Healthcare Conference 2021
|
|
|
|
August 27, 2021
Redeye interviews CEO Peter Zerhouni after the release of the Q2 report
|
|
|
|
June 15, 2021
Interview with CEO Peter Zerhouni about the phase III study CONCLUDE
|
|
|
|
June 2, 2021
Presentation at Redeye Growth Day
|
|
|
|
May 6, 2021
Presentation at Erik Penser Bank's theme day - commercialization of medicines
|
|
|
|
March 11, 2021
Presentation at Barclays Global Healthcare Conference
|
|
|
|
January 28, 2021
Redeye interviews CEO Peter Zerhouni about the latest events in the company and the plans for 2021
|
|
|
|
January 7, 2021
Interview with InDex CEO Peter Zerhouni about the eventful year 2020 and what awaits in 2021
|
|
|
|
December 8, 2020
InDex Pharmaceuticals R&D day
|
|
|
|
November 26, 2020
Presentation at Redeye Life Science Day
|
|
|
|
October 12, 2020
Presentation of CONDUCT study at UEGW and ACG
|
|
|
|
October 6, 2020
Interview with InDex about the publication of the phase IIb CONDUCT study results in the Lancet Gastroenterology and Hepatology
|
|
|
|
October 6, 2020
Redeye interviews CMO Dr Thomas Knittel about the publication of the CONDUCT study results in the Lancet Gastroenterology and Heptology
|
|
|
|
September 24, 2020
Interview with CEO Peter Zerhouni at Bolagsdagen Erik Penser Bank
|
|
|
|
September 24, 2020
Presentation at Bolagsdagen Erik Penser Bank
|
|
|
|
September 2, 2020
Interview with CEO Peter Zerhouni at Pareto Securities Healthcare Conference
|
|
|
|
June 2, 2020
Presentation at Redeye Growth Day 2020
|
|
|
|
May 4, 2020
Interview with CEO Peter Zerhouni in Nordic Life Science News
|
|
|
|
April 29, 2020
Interview with CEO Peter Zerhouni about the market research studies with physicians and patients
|
|
|
|
April 20, 2020
Teleconference – update on the phase III preparations
|
|
|
|
February 20, 2020
Interview with Professor Walter Reinisch on the results of the CONDUCT-study
|
|
|
|
February 20, 2020
CEO interview on the conclusions from the in-depth analysis of the CONDUCT study
|
|
|
|
December 12, 2019
Investor presentation at Redeye
|
|
|
|
November 19, 2019
Presentation at Avanza Börsdag
|
|
|
|
November 19, 2019
Presentation at Redeye Life Science Day
|
|
|
|
September 17, 2019
CEO Interview at Redeye
|
|
|
|
September 5, 2019
CEO Interview at Pareto Health Care Conference
|
|
|
|
September 5, 2019
Presentation at Pareto Health Care Conference
|
|
|
|
August 27, 2019
Presentation of CONDUCT top line results
|
|
|
|
August 27, 2019
CEO Inteview at Di TV
|
|
|
|
June 26, 2019
CEO Interview at Redeye
|
|
|
|
June 18, 2019
CEO Interview at Healthcare Direkt
|
|
|
|
June 10, 2019
Redeye Growth Day 2019
|
|
|
|
December 3, 2018
Redeye Investor After Work in Gothenburg
|
|
|
|
November 21, 2018
Redeye Life Science Seminar 2018
|
|
|
|
April 25, 2018
Capital Markets Day 2018
|
|
|
|
March 7, 2018
Stockholm Corporate Finance Life Science Seminar 2018
|
|
|
|
November 24, 2017
Redeye Life Science Seminar 2017
|
|
|
|
June 28, 2017
CEO Interview by Finwire
|
|
|
|
June 27, 2017
CEO Interview by Redeye
|
|
|
|
June 12, 2017
Småbolagsdagen 2017
|
|
|
|
April 27, 2017
Redeye Biotech Seminar 2017
|
|
|
|
March 22, 2017
Stockholm Corporate Finance Life Science Seminar 2017
|
|
|
|
November 15, 2016
Redeye Life Science Seminar 2016
|
|
|
|
October 11, 2016
Listing on First North Nasdaq Stockholm
|
|
|
|
September 14, 2016
Biostock Academy meets InDex Pharmaceuticals
|
|
|
|
September 12, 2016
Aktiedagen 2016
|
|
|
|
August 24, 2016
CEO Interview by Finwire
|
|
|
|
Deep dive presentation on the positive feedback from the Japanese regulatory authority on cobitolimod
|
|
|
SVE
ENG
